Literature DB >> 23013385

Prevalence of multidrug-resistant gram-negative bacilli producing extended-spectrum β-lactamases (ESBLs) and ESBL genes in solid organ transplant recipients.

T-Y Men1, J-N Wang, H Li, Y Gu, T-H Xing, Z-H Peng, L Zhong.   

Abstract

BACKGROUND: Multidrug-resistant (MDR) gram-negative bacilli pose a serious and rapidly emerging threat to recipients of solid organ transplants (SOTs). However, extended-spectrum β-lactamases (ESBLs), as one of the cardinal mechanisms of resistance to antimicrobial agents in SOT recipients, remain obscure. The aim of this study was to investigate the prevalence of strains producing ESBLs in SOT patients with MDR gram-negative bacilli infections and to identify the ESBL genes carried by them.
MATERIALS AND METHODS: Isolates from various clinical specimens of SOT recipients were identified using the VITEK 2 system, and their antibiotic sensitivity was determined by the 2-fold agar dilution method. Isolates suspected of producing ESBL enzymes were tested by an ESBL phenotypic confirmatory method, and the ESBL genotypes were determined by the polymerase chain reaction and sequencing.
RESULTS: A total of 80 MDR gram-negative strains were isolated from 350 SOT recipients. Among these strains, 42 (52.5%) had an ESBL-positive phenotype; 33 (42.3%) patients with ESBL-positive infection were found. Molecular analysis showed that most of the isolates harbored blaCTX-M-9 (78.6%), blaTEM (81.0%), and blaSHV (69.0%) genes. All the ESBL-producing strains were susceptible to carbapenems.
CONCLUSIONS: MDR gram-negative isolates from SOT recipients are frequently ESBL producers. TEM and CTX-M9 were the predominant ESBL types.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23013385     DOI: 10.1111/tid.12001

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  8 in total

1.  Immunity of fungal infections alleviated graft reject in liver transplantation compared with non-fungus recipients.

Authors:  Tonghai Xing; Lin Zhong; Lihui Lin; Guoqiang Qiu; Zhihai Peng
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge.

Authors:  Guilherme Santoro-Lopes; Erika Ferraz de Gouvêa
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 3.  Bacterial infection after liver transplantation.

Authors:  Sang Il Kim
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

4.  Factors influencing mortality in abdominal solid organ transplant recipients with multidrug-resistant gram-negative bacteremia.

Authors:  Bingbing Qiao; Jianzhen Wu; Qiquan Wan; Sheng Zhang; Qifa Ye
Journal:  BMC Infect Dis       Date:  2017-02-27       Impact factor: 3.090

Review 5.  Challenges of Antimicrobial Resistance and Stewardship in Solid Organ Transplant Patients.

Authors:  Miranda So; Laura Walti
Journal:  Curr Infect Dis Rep       Date:  2022-04-30       Impact factor: 3.663

6.  Multidrug-resistant organisms: A significant cause of severe sepsis in pediatric intestinal and multi-visceral transplantation.

Authors:  Alicia M Alcamo; Mira K Trivedi; Carly Dulabon; Christopher M Horvat; Geoffrey J Bond; Joseph A Carcillo; Michael Green; Marian G Michaels; Rajesh K Aneja
Journal:  Am J Transplant       Date:  2021-07-28       Impact factor: 8.086

7.  C7 genotype of the donor may predict early bacterial infection after liver transplantation.

Authors:  Lin Zhong; Hao Li; Zhiqiang Li; Baojie Shi; PuSen Wang; ChunGuang Wang; Junwei Fan; Hongcheng Sun; Peiwen Wang; Xuebin Qin; Zhihai Peng
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

8.  High prevalence of multidrug-resistant gram-negative bacterial infection following pediatric liver transplantation.

Authors:  Chanita Phichaphop; Nopporn Apiwattanakul; Chonnamet Techasaensiri; Chatmanee Lertudomphonwanit; Suporn Treepongkaruna; Chollasak Thirapattaraphan; Sophida Boonsathorn
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.